摘要
第1个血管紧张素受体-脑啡肽酶抑制剂(ARNI)代表药沙库巴曲/缬沙坦(LCZ696)是2018年心力衰竭指南中新增的药物治疗推荐。指南中指出,血肌酐>221μmol/L(2.5 mg/dl)或估算肾小球滤过率(eGFR)<30 ml/(min·1.73 m2)的患者慎用ARNI,可见ARNI对肾功能的影响。该文总结现有的动物实验和临床研究,综述LCZ696对肾脏的影响。LCZ696虽然可能引起尿白蛋白比肌酐比值(UACR)的轻微升高,但是LCZ696能够延缓eGFR的下降和肾功能恶化,降低血压,改善肾脏组织病理,且具有良好的安全性和耐受性。
LCZ696,the first ARNI,was recommended as a new drug in the 2018 Heart failure guidelines.The guidelines point out that patients with serum creatinine>221 umol/L(2.5 mg/dl)or eGRF<30 ml/(min·1.73 m2)are careful to use ARNI.It can be seen that the effect of ARNI on renal function is very important in the safety and efficacy of treatment.In this paper,the effects of LCZ696 on kidney were reviewed.The results showed that LCZ696 might cause a slight increase in UACR,but LCZ696 could slow down the decline of eGFR,delay the deterioration of renal function,lower blood pressure,improve renal pathology,and have good safety and tolerance.
作者
张雪
杜玄一
Xue Zhang;Xuan-yi Du(Department of Nephrology,The Second affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang 150086,China)
出处
《中国现代医学杂志》
CAS
2020年第9期60-64,共5页
China Journal of Modern Medicine
